Real Endpoints Recent Developments
Cardiologists bemoaned high cost of new drugs and high hurdles for reimbursement at the American College of Cardiology annual meeting; will outcomes data save the day?Learn More
One of the big ideas in biotech today is that you can prevent severe, chronic migraine headaches. This story has a lot of juicy ingredients: intriguing biology, bona fide medical value, and a potentially broad impact on millions of people.Learn More
Newest hepatitis C entrant doesn’t have the best value in all subpopulations, according to analysis by RealEndpoints, but Medicaid’s mandatory discount could make up for those disadvantages.Learn More
Forbes, Pharma & Healthcare, March 24, 2016 by Luke Timmerman
The Dream Team That Could Fix Drug Pricing
Please click here to read full article.Learn More
Despite discount, Merck’s just approved Zepatier unlikely to win share with most US payers, except in Medicaid, according to RxScorecard™.
New combo from Gilead could ensure company’s dominant position among US payers.
Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened.Learn More